Mosaic chemotherapy strategies for developing ALS/MND therapeutic approaches: beta-2 adrenergic agonists.
Brooks
B R
BR
Department of Neurology, University of Wisconsin Hospital & Clinics, UW Health System, School of Medicine, University of Wisconsin-Madison 53792-5132, USA.
Juhasz-Poscine
K
K
Waclawik
A
A
Sanjak
M
M
Belden
D
D
Roelke
K
K
Parnell
J
J
Weasler
C
C
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D002976:Clenbuterol / Q000627:therapeutic use*; D006801:Humans
D058666:Adrenergic beta-2 Receptor Agonists; D000318:Adrenergic beta-Agonists; D002976:Clenbuterol